Home » Newsletters » BioWorld Science

BioWorld Science

April 16, 2008

View Archived Issues

Jerini and PR collaborate on sustained-release formulations of ophthalmic drugs

BiPar Sciences expands clinical program for BSI-201 into glioblastoma multiforme

Preclinical activity of ENMD-2076 described

Galderma acquires CollaGenex

European Commission approves Effentora for breakthrough cancer pain

ChemGenex to submit rolling NDA to the FDA for omacetaxine mepesuccinate in CML

Lpath submits IND application to FDA for iSONEP in age-related macular degeneration

Jazz Pharmaceuticals' Luvox now available in the U.S. for treatment of SAD and OCD

Johnson & Johnson submits supplemental NDA for Risperdal Consta in FRBD

Isis reports additional results from phase II study of mipomersen in familial hypercholesterolemia

Medgenics to initiate phase I/II clinical trials in Israel of Epodure in anemia

Tolfenamic acid active against pancreatic cancer cells and tumors

H3 antagonists developed at Wyeth for cognitive dysfunction

Hdm2 antagonist JNJ-26854165 shows in vivo antitumor activity

Novel oral calcium receptor antagonists demonstrate bone formation activity in initial studies

HHS clears Iomai to begin phase II study of H5N1 adjuvant patch

FDA awards orphan drug designation for Rhitol in chronic GvHD

Silenor insomnia NDA accepted for filing

AnGes launches Naglazyme for mucopolysaccharidosis VI in Japan

Actemra approved in Japan to treat patients with rheumatoid arthritis

Humira approved in Japan for the treatment of rheumatoid arthritis

New therapeutic option for glaucoma reported in recent Organon patent

Recent Janssen patent discloses new therapeutic agents for benign prostatic hyperplasia

Recent Pfizer and Kyorin patents describe new agents for treating respiratory disorders

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...